Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review
Objectives: Psoriasis is a chronic inflammatory skin disorder and the efficacy and safety of Chinese herbal medicine (CHM) treatments is unclear. This review evaluates oral CHM for psoriasis vulgaris clinical trial evidence. Design: The Cochrane Library, PubMed, EMBASE, CINAHL, AMED, CBM, CNKI, CQVI...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-01-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2016.1178377 |
| _version_ | 1797684030560272384 |
|---|---|
| author | Shefton Parker Claire Shuiqing Zhang Jason Jingjie Yu Chuanjian Lu Anthony Lin Zhang Charlie C. Xue |
| author_facet | Shefton Parker Claire Shuiqing Zhang Jason Jingjie Yu Chuanjian Lu Anthony Lin Zhang Charlie C. Xue |
| author_sort | Shefton Parker |
| collection | DOAJ |
| description | Objectives: Psoriasis is a chronic inflammatory skin disorder and the efficacy and safety of Chinese herbal medicine (CHM) treatments is unclear. This review evaluates oral CHM for psoriasis vulgaris clinical trial evidence. Design: The Cochrane Library, PubMed, EMBASE, CINAHL, AMED, CBM, CNKI, CQVIP and Wanfang databases were searched from inception to June 2015. Randomised controlled trials (RCTs) of oral CHM compared to placebo data were included and analysed using Review Manager 5.2. Results: Seven studies were included, no study utilised identical CHM intervention. Four studies data were subgrouped (decoction or capsule/pill) and pooled in meta-analysis to evaluate treatment effective rate for PASI60 or above (RR: 2.74 [0.92, 8.21] I2 = 65%). Another five studies were subgrouped and evaluated for PASI score change, (MD −7.00 [−10.74, −3.27] I2 = 98%). Only one study presented Dermatology Life Quality Index data, which favoured CHM (MD: −4.08 [−7.56, −0.60]). Two studies presented data on psoriasis-related inflammatory cell-signalling protein tumour necrosis factor-a (TNF-a) (MD: −4.92 [−5.31, −4.53]). No serious adverse events were reported. Conclusion: While CHMs appear to be safe and may have benefit for psoriasis, variation between CHM interventions, outcome measures and the quality of included studies limit the conclusions of this review. Further rigorous RCTs utilising reliable, validated symptom and QoL outcome measures are recommended. |
| first_indexed | 2024-03-12T00:23:28Z |
| format | Article |
| id | doaj.art-d07a118173d84dd983cbd4942d3224f6 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:23:28Z |
| publishDate | 2017-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-d07a118173d84dd983cbd4942d3224f62023-09-15T10:48:02ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532017-01-01281213110.1080/09546634.2016.11783771178377Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic reviewShefton Parker0Claire Shuiqing Zhang1Jason Jingjie Yu2Chuanjian Lu3Anthony Lin Zhang4Charlie C. Xue5China-Australia International Research Centre for Chinese Medicine, RMIT UniversityChina-Australia International Research Centre for Chinese Medicine, RMIT UniversityChina-Australia International Research Centre for Chinese Medicine, RMIT UniversityChina-Australia International Research Centre for Chinese Medicine, RMIT UniversityChina-Australia International Research Centre for Chinese Medicine, RMIT UniversityChina-Australia International Research Centre for Chinese Medicine, RMIT UniversityObjectives: Psoriasis is a chronic inflammatory skin disorder and the efficacy and safety of Chinese herbal medicine (CHM) treatments is unclear. This review evaluates oral CHM for psoriasis vulgaris clinical trial evidence. Design: The Cochrane Library, PubMed, EMBASE, CINAHL, AMED, CBM, CNKI, CQVIP and Wanfang databases were searched from inception to June 2015. Randomised controlled trials (RCTs) of oral CHM compared to placebo data were included and analysed using Review Manager 5.2. Results: Seven studies were included, no study utilised identical CHM intervention. Four studies data were subgrouped (decoction or capsule/pill) and pooled in meta-analysis to evaluate treatment effective rate for PASI60 or above (RR: 2.74 [0.92, 8.21] I2 = 65%). Another five studies were subgrouped and evaluated for PASI score change, (MD −7.00 [−10.74, −3.27] I2 = 98%). Only one study presented Dermatology Life Quality Index data, which favoured CHM (MD: −4.08 [−7.56, −0.60]). Two studies presented data on psoriasis-related inflammatory cell-signalling protein tumour necrosis factor-a (TNF-a) (MD: −4.92 [−5.31, −4.53]). No serious adverse events were reported. Conclusion: While CHMs appear to be safe and may have benefit for psoriasis, variation between CHM interventions, outcome measures and the quality of included studies limit the conclusions of this review. Further rigorous RCTs utilising reliable, validated symptom and QoL outcome measures are recommended.http://dx.doi.org/10.1080/09546634.2016.1178377psoriasisherbrandomcontroltrialreview |
| spellingShingle | Shefton Parker Claire Shuiqing Zhang Jason Jingjie Yu Chuanjian Lu Anthony Lin Zhang Charlie C. Xue Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review Journal of Dermatological Treatment psoriasis herb random control trial review |
| title | Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review |
| title_full | Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review |
| title_fullStr | Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review |
| title_full_unstemmed | Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review |
| title_short | Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review |
| title_sort | oral chinese herbal medicine versus placebo for psoriasis vulgaris a systematic review |
| topic | psoriasis herb random control trial review |
| url | http://dx.doi.org/10.1080/09546634.2016.1178377 |
| work_keys_str_mv | AT sheftonparker oralchineseherbalmedicineversusplaceboforpsoriasisvulgarisasystematicreview AT claireshuiqingzhang oralchineseherbalmedicineversusplaceboforpsoriasisvulgarisasystematicreview AT jasonjingjieyu oralchineseherbalmedicineversusplaceboforpsoriasisvulgarisasystematicreview AT chuanjianlu oralchineseherbalmedicineversusplaceboforpsoriasisvulgarisasystematicreview AT anthonylinzhang oralchineseherbalmedicineversusplaceboforpsoriasisvulgarisasystematicreview AT charliecxue oralchineseherbalmedicineversusplaceboforpsoriasisvulgarisasystematicreview |